Perioperative systemic therapy in high-risk renal cell carcinoma following nephrectomy: a narrative review.

ABSTRACT:

Background and objective

For patients with resectable renal cell carcinoma (RCC), extirpative surgery with curative intent remains the standard of care. Despite surgical resection, most patients with high-risk features experience disease recurrence. The role of perioperative systemic therapy in the management of these patients' disease remains unclear. Several studies have evaluated the efficacy and safety of tyrosine kinase inhibitors (TKIs); however, most trials have yielded negative results. Adjuvant pembrolizumab demonstrated a disease-free survival benefit in the KEYNOTE-564 trial; however, multiple studies of other immune checkpoint inhibitors (ICIs) in a similar patient population did not yield consistent results. This review summarizes the current evidence for perioperative

SUBMITTER: Khorasanchi A 

PROVIDER: S-EPMC11651769 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature